Novo Nordisk taps Microsoft’s AI to boost drug discovery
Novo Nordisk taps Microsoft’s AI to boost drug discovery
Source: Fierce Biotech By Andrea Park
Artificial intelligence has increasingly become a go-to tool—rather than a novelty—for drugmakers looking to build the next generation of groundbreaking therapeutics.
Big Pharmas around the world are forging partnerships to apply AI technology to their drug discovery and development processes, including Novo Nordisk, which announced Monday that it has inked a deal with Microsoft to speed up its drug discovery work.
The collaboration will span several years and will see Microsoft lend its AI and other cloud-based data analytics tools to Novo’s R&D department. The companies said they’re planning to take a “platform approach” in their tech partnership, meaning that they’ll develop broad AI models that they can adapt and apply to a wide variety of tasks as time goes on.
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
The Washington Post Reports That DEA Claims It Seized Enough Fentanyl to Kill Us All
While Law Enforcement Address Supply Issues, GATC Health Joins Fight Against Demand With Novel Addiction Treatments Of the 107,000 people w…
Read more
GATC Health Welcomes the FDA Modernization Act 2.0, Allowing New Drug Candidates to Bypass Animal Testing Using Computer Modeling
This legislation is expected to create more demand for GATC’s drug discovery and development platform as AI and machine learning are increa…
Read more
GATC Health Announces Tyrone Lam as Chief Operating Officer
GATC Health, a science and technology company focused on whole genome analysis and Predictive Multiomics™, today announced that Tyrone Lam …
Read more